<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04409145</url>
  </required_header>
  <id_info>
    <org_study_id>VT30-101</org_study_id>
    <nct_id>NCT04409145</nct_id>
  </id_info>
  <brief_title>First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations</brief_title>
  <official_title>Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Venthera, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Venthera, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      VT30-101 is a 2-part first-in-human trial of topically administered VT30 to subjects with
      cutaneous venous malformations, lymphatic malformations, or mixed venolymphatic malformations
      associated with PIK3CA or TEK mutations.

      Part 1 is a 4-week treatment, open-label, 4-sequence, escalating repeat-application cohort
      study, with intra-subject and inter-cohort dose escalation.

      Part 2 is a 12-week treatment, randomized, placebo-controlled, double-blind, safety and
      exploratory efficacy study. Part 2 will be initiated only after the successful completion of
      Part 1 with results that demonstrate the general safety and tolerability of topically applied
      VT30. Up to 12 subjects who complete Part 1 may be enrolled into Part 2 of the study.

      The primary objective is to evaluate the safety and tolerability of VT30. The study will also
      determine the dose and regimen of VT30 to be carried into Part 2 of the protocol. Other aims
      include documenting plasma drug levels of VT30 and VT10 and, on an exploratory basis,
      examining pharmacologic target engagement and change in potential efficacy readouts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VT30-101 is designed as a Phase 1/2, first-in-human study of topically administered VT30 to
      subjects with cutaneous venous malformations (VMs), lymphatic malformations (LMs), or mixed
      venolymphatic malformations (VLMs) associated with phosphatidylinositol 3-kinase catalytic
      alpha polypeptide (PIK3CA) or tyrosine receptor kinase (TEK) mutations. Capillary involvement
      and/or extension of the lesion into subcutaneous tissues is permitted.

      The study will occur in 2 parts, and in both study parts, subjects will participate in a
      Screening Period (up to 6 weeks) before beginning the indicated Treatment Period.

      Part 1 will be an open-label, 4-sequence, escalating repeat-application study comprised of up
      to 4 cohorts (3 subjects per cohort, with 3 up to 6 in Cohort 4, or the final Part 1 cohort).
      In each cohort, subjects will be given topical VT30 for a 4-week Treatment Period. Subjects
      will begin treatment with the designated dose on Day 1. After 2 weeks, the Investigator will
      examine the treated surface area and determine if the formulation is tolerated such that the
      subject may apply the next dose strength of VT30 gel for the remaining duration of the
      Treatment Period.

      Specifically, the following gel dose strengths (concentrations) are planned for Cohorts 1
      through 3 in Part 1:

        -  Cohort 1: initiate dosing with 0.12% (w/w) gel and progress to 0.6% (w/w) gel for the
           final 2 weeks of the Part 1 Treatment Period (if the lower dose is tolerated)

        -  Cohort 2: initiate dosing with 0.6% (w/w) gel and progress to 1.2% (w/w) gel for the
           final 2 weeks of the Part 1 Treatment Period (if the lower dose is tolerated)

        -  Cohort 3: initiate dosing with 1.2% (w/w) gel and progress to 2.3% (w/w) gel for the
           final 2 weeks of the Part 1 Treatment Period (if the lower dose is tolerated)

      A Safety Review Committee (SRC), with sponsor, investigator and independent medical
      representation, will provide oversight and guidance for study conduct. After 3 subjects have
      been dosed for at least 21 days in any of the first three Part 1 cohorts, the SRC may request
      additional data, approve initiation of the subsequent cohort, or mandate that additional
      subjects to be enrolled at either the higher or lower dose within the cohort.

      After 9 subjects in Cohorts 1 through 3 (3 subjects per cohort) have completed the 4-week
      Treatment Period, the SRC will determine if additional subjects should be assigned to Cohort
      4 (or the final Part 1 cohort) to receive the MTD (maximum tolerated dose) or MFD (maximum
      feasible dose) strength of VT30. Subjects in Cohort 4 will receive the designated dose
      strength and regimen of VT30 for a full 4 weeks.

      Following the completion of Cohort 4 in Part 1, the SRC will determine whether to authorize
      initiation of Part 2 and will confirm the dose level and regimen to be administered in Part
      2.

      Part 2 will be a randomized, placebo-controlled, double-blind study containing 36 subjects
      assigned in a 2:1 ratio to receive either VT30 or placebo. Up to 12 subjects who complete
      Part 1 may enroll in Part 2, provided they meet all Part 2-specific inclusion criteria with
      no applicable exclusions.

      After the first 12 subjects in Part 2 have completed 4 weeks of treatment, the SRC will
      conduct a review of blinded safety data to confirm no revisions or changes are needed to the
      protocol. Subsequent reviews may also be conducted to ensure continued acceptable safety and
      tolerability.

      After subjects complete their designated Treatment Period (in Part 1 or Part 2), they will
      participate in a 4-week post treatment Follow-up Period.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Part 1: Open-label, 4-sequence, escalating repeat-application cohort study, with intra-subject and inter-cohort dose escalation to determine safety and tolerability, and maximum feasible dose/maximum tolerable dose Part 2: Randomized, placebo-controlled, double-blind, safety and exploratory efficacy study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Part 1: Open label Part 2: Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of safety and tolerability</measure>
    <time_frame>From pre-treatment to 4 weeks of treatment</time_frame>
    <description>Composite of adverse events and changes in physical exam findings, vital signs, lab tests, and electrocardiogram evaluations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum feasible dose / maximum tolerable dose</measure>
    <time_frame>From pre-treatment to 4 weeks</time_frame>
    <description>The MTD or MFD strength will be determined based on results from Part 1, and will inform the dose strength to be used in Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue and serum drug levels</measure>
    <time_frame>From pre-treatment to 4 weeks</time_frame>
    <description>Plasma levels of VT30 and VT10 will be assessed following topical administration of VT30 to determine level of systemic exposure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Maximum tissue concentration of study drug</measure>
    <time_frame>From pre-treatment to 4 weeks</time_frame>
    <description>As assessed by treated lesion tissue levels of phosphoproteins, as an indicator of local target engagement</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Pain</measure>
    <time_frame>From pre-treatment to 4 weeks</time_frame>
    <description>Assessed by subjects' self-reporting their pain, related to the treated lesion, on a Numerical Rating Scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in lesion</measure>
    <time_frame>From pre-treatment to 4 weeks</time_frame>
    <description>Assessed by change in appearance of the treated lesion</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in management of lesion bleeding, oozing, or discharge</measure>
    <time_frame>From pre-treatment to 4 weeks</time_frame>
    <description>Assessed by subject-reported difficulty managing bleeding, oozing, or discharge from the treated lesion</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Venous Malformation</condition>
  <condition>Lymphatic Malformation</condition>
  <condition>Venolymphatic Malformation</condition>
  <arm_group>
    <arm_group_label>VT30</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VT30 is a PI3K-inhibitor prodrug, formulated as a topical gel and dispensed from a metered dose pump; administration is once or twice daily, applied to target-treatment area(s) on the skin. One pump action dispenses 250 ÂµL of gel, intended to treat an area of 140 cm2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VT30</intervention_name>
    <description>VT30 gel is intended as a topical treatment of cutaneous VMs, LMs, or VLMs that driven by inappropriate PI3K activation. In the skin, VT30 is rapidly metabolized to VT10, an active drug form, and is intended to sufficiently permeate the stratum corneum and achieve target engagement. It is expected that VT30 will lead to amelioration of the signs and symptoms of cutaneous VMs, LMs and/or VLMs.</description>
    <arm_group_label>VT30</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have signed the current approved informed consent form

          2. Have a clinically or phenotypically defined VM, LM, or mixed VLM affecting the skin

          3. Lesion genotyping confirms either PIK3CA or TEK mutations, known to be pathogenic

          4. Agrees to use contraception if of childbearing potential

          5. Be willing and able to comply with the protocol and be available for the entire study

          6. Be at least 18 to 60 years of age

          7. Lesion must be amenable to defining a contiguous study treatment area of 140 cm2

        Exclusion Criteria:

          1. Lesion to be treated is on the face or involves mucosa

          2. Presence of ulcerations on the target-treatment lesion

          3. Known systemic hypersensitivity to the VT30 drug substance, its inactive ingredients,
             or the vehicle

          4. Uncontrolled diabetes mellitus

          5. Hyperlipidemia that is poorly controlled on current treatment

          6. Pregnant or nursing, planning to become pregnant, or planning to father a child during
             the study

          7. History of malignancy except successfully treated nonmetastatic cutaneous squamous
             cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix

          8. Major surgery within 8 weeks of Screening, or a surgical, laser or other procedure
             involving the target lesion within 8 weeks of Screening, or planned to occur during
             the study

          9. Any other medical or personal condition that, in the opinion of the Investigator, may
             potentially compromise the safety or compliance of the subject, or may preclude the
             subject's successful completion of the clinical study

         10. Medically significant infection (eg, cellulitis or abscess, or a systemic infection)
             within 8 weeks of Screening

         11. Ongoing therapy with another topical treatment or any medication that inhibits PI3K,
             Akt pathway, or the mTOR pathway, or in the opinion of the Investigator, the subject
             requires systemic therapy for their vascular malformation condition

         12. Use of a biologic or systemic immunosuppressive agent within 3 months of Screening

         13. Systemic use of corticosteroids, within 30 days of Screening

         14. Treatment with a small molecule investigational product within 30 days of Screening,
             or with any investigational biologic products within 3 months of Screening

         15. Positive for hepatitis C antibody, hepatitis B surface antigen, hepatitis B core
             antibody, or human immunodeficiency virus

         16. Alanine transaminase or aspartate transaminase laboratory values in excess of 1.5X the
             upper limit of normal at Screening

         17. Hemoglobin A1c is &gt;8%

         18. Any other clinically significant laboratory or testing abnormality that, in the
             opinion of the Investigator, might confound the study, interfere with the subject's
             ability to complete the study, or represent a meaningful safety risk upon study
             enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2020</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphangioma</mesh_term>
    <mesh_term>Lymphatic Abnormalities</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

